DK0931830T3 - Cytopatiske vira til terapi og profylakse af neoplasi - Google Patents

Cytopatiske vira til terapi og profylakse af neoplasi

Info

Publication number: DK0931830T3
Authority: DK; Denmark
Prior art keywords: replication phenotype; cells; neoplastic cells; viral; neoplastic
Prior art date: 1993-02-16

Application number

DK98121753T

Other languages

English (en)

Inventor

Francis Mccormick

Original Assignee

Onyx Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-16

Filing date

1994-02-16

Publication date

2001-06-11

1994-02-16 Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc

2001-06-11 Application granted granted Critical

2001-06-11 Publication of DK0931830T3 publication Critical patent/DK0931830T3/da

Links

241000700605 Viruses Species 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title abstract 2
230000000120 cytopathologic effect Effects 0.000 title 1
230000009826 neoplastic cell growth Effects 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
210000005170 neoplastic cell Anatomy 0.000 abstract 4
230000010076 replication Effects 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 2
108010067390 Viral Proteins Proteins 0.000 abstract 1
208000035269 cancer or benign tumor Diseases 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000003362 replicative effect Effects 0.000 abstract 1
230000029812 viral genome replication Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK98121753T 1993-02-16 1994-02-16 Cytopatiske vira til terapi og profylakse af neoplasi DK0931830T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1752593A	1993-02-16	1993-02-16

Publications (1)

Publication Number	Publication Date
DK0931830T3 true DK0931830T3 (da)	2001-06-11

Family

ID=21783090

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK98121753T DK0931830T3 (da)	1993-02-16	1994-02-16	Cytopatiske vira til terapi og profylakse af neoplasi
DK94910177T DK0689447T3 (da)	1993-02-16	1994-02-16	Cytopatiske vira til behandling af og profylakse for neoplasia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK94910177T DK0689447T3 (da)	1993-02-16	1994-02-16	Cytopatiske vira til behandling af og profylakse for neoplasia

Country Status (11)

Country	Link
EP (2)	EP0931830B1 (da)
JP (2)	JP3556666B2 (da)
AT (2)	ATE178490T1 (da)
AU (1)	AU682854B2 (da)
CA (1)	CA2152941C (da)
DE (2)	DE69426841T2 (da)
DK (2)	DK0931830T3 (da)
ES (2)	ES2157109T3 (da)
GR (2)	GR3030385T3 (da)
PT (1)	PT931830E (da)
WO (1)	WO1994018992A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747469A (en)	1991-03-06	1998-05-05	Board Of Regents, The University Of Texas System	Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en)	1992-10-13	2002-06-25	Board Of Regents, The University Of Texas System	Recombinant P53 adenovirus compositions
AU663702B2 (en)	1991-03-06	1995-10-19	Board Of Regents, The University Of Texas System	Methods and compositions for the selective inhibition of gene expression
US5516631A (en) *	1992-10-13	1996-05-14	La Jolla Cancer Research Foundation	Method of inhibiting replication of hyperproliferative cells
PT696326E (pt)	1993-04-30	2003-08-29	Wellstat Biologics Corp	Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
US5776743A (en)	1994-09-06	1998-07-07	La Jolla Cancer Research Foundation	Method of sensitizing tumor cells with adenovirus E1A
US6638762B1 (en)	1994-11-28	2003-10-28	Genetic Therapy, Inc.	Tissue-vectors specific replication and gene expression
US5998205A (en)	1994-11-28	1999-12-07	Genetic Therapy, Inc.	Vectors for tissue-specific replication
EP0791050B1 (en) *	1994-11-28	2006-02-15	Cell Genesys Inc.	Vectors for tissue-specific replication
US6326356B1 (en)	1996-10-18	2001-12-04	Board Of Regents, The University Of Texas System	Suppression of neu overexpression using a mini-E1A gene
US20030026789A1 (en) *	1995-05-03	2003-02-06	Richard J. Gregory	Gene therapy using replication competent targeted adenoviral vectors
WO1997007828A1 (en) *	1995-08-30	1997-03-06	The Regents Of The University Of California	Therapy for cellular accumulation in chronic inflammatory diseases
US6133243A (en) *	1996-02-22	2000-10-17	Onyx Pharmaceuticals, Inc.	Liposomal-viral DNA complexes for treating disease
US6054467A (en) *	1996-07-05	2000-04-25	Sidney Kimmel Cancer Center	Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en)	1996-07-30	1999-09-28	Board Of Regents, The University Of Texas System	2-methoxyestradiol-induced apoptosis in cancer cells
AU4592697A (en) *	1996-09-24	1998-04-17	Dana-Farber Cancer Institute	Method of targeting malignant cells using an e2f responsive promoter
AU742696B2 (en) *	1996-11-18	2002-01-10	Mcgill University	Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
US6080578A (en) *	1996-12-31	2000-06-27	Onyx Pharmaceuticals, Inc.	Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en)	1997-02-10	2002-06-11	Genstar Therapeutics Corporation	Oncolytic/immunogenic complementary-adenoviral vector system
US6136307A (en)	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en)	1999-02-24	2003-05-20	Oncolytics Biotech Inc.	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) *	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6696423B1 (en)	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US6020135A (en)	1998-03-27	2000-02-01	Affymetrix, Inc.	P53-regulated genes
US7691370B2 (en)	1998-10-15	2010-04-06	Canji, Inc.	Selectivity replicating viral vector
SK4412001A3 (en) *	1998-10-15	2001-12-03	Canji Inc	Selectively replicating viral vectors
EP1121442A2 (en) *	1998-10-15	2001-08-08	CANJI, Inc.	Recombinant e1a deleted adenoviral vectors
US20020037274A1 (en) *	1998-10-26	2002-03-28	Angelica Williams	Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
AU2145300A (en) *	1998-11-18	2000-06-05	Canji, Inc.	Adenoviral vectors
GB9906815D0 (en) *	1999-03-24	1999-05-19	Isrec	Anti-neoplastic viral agents
NZ550861A (en)	1999-04-15	2009-03-31	Wellstat Biologics Corp	Treatment of neoplasms with viruses
DE19929569A1 (de) *	1999-06-21	2000-12-28	Holm Per Sonne	Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
AU776061B2 (en) *	1999-11-15	2004-08-26	Onyx Pharmaceuticals	An oncolytic adenovirus
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) *	2002-06-28	2007-12-11	Oncolyties Biotech Inc.	Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en)	2000-05-03	2013-07-23	Oncolytics Biotech Inc.	Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es)	2000-05-03	2003-04-23	Oncolytics Biotech Inc	Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR035227A1 (es)	2001-02-20	2004-05-05	Oncolytics Biotech Inc	Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
JP2004536572A (ja)	2001-02-23	2004-12-09	セル・ジェネシス・インコーポレイテッド	新規ベクター構築物
CA2374388C (en)	2002-02-28	2005-07-12	Matthew C. Coffey	The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en)	2002-02-28	2004-01-08	Oncolytics Biotech Inc.	Use of ribozymes in the detection of adventitious agents
EP1944035A1 (en)	2002-05-09	2008-07-16	Oncolytics Biotech Inc.	Method for reducing pain using oncolytic viruses
RU2351361C2 (ru) *	2002-05-27	2009-04-10	Пер Сонне ХОЛЬМ	Новое применение аденовируса и кодирующих его нуклеиновых кислот
US20060099178A1 (en) *	2002-05-27	2006-05-11	Holm Per S	Novel use of adenoviruses and nucleic acids coding therefor
AU2011221393A1 (en) *	2002-05-27	2011-09-29	Per Sonne Holm	Novel use of adenoviruses and nucleic acids coding therefor
SG165168A1 (en) *	2002-10-15	2010-10-28	Sonne Holm	New adenoviruses, nucleic acids coding therefor and their use
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CN1826410B (zh)	2003-07-21	2011-10-26	特兰斯吉恩股份有限公司	具有改良的胞嘧啶脱氨酶活性的多肽
EP1689445B1 (de)	2003-11-14	2015-02-25	Per Sonne Holm	Neue verwendung von adenoviren und dafür codierende nukleinsäuren
KR100756055B1 (ko)	2006-01-27	2007-09-07	연세대학교 산학협력단	신생혈관 생성을 조절하는 재조합 아데노바이러스
US8470977B2 (en)	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
MX2011007494A (es)	2009-01-13	2011-08-12	Transgene Sa	Uso de una fraccion de la mitocondria de acidos nucleicos de saccharomyces cerevisiae para la estimulacion inmune.
ES2385251B1 (es)	2009-05-06	2013-05-06	Fundació Privada Institut D'investigació Biomèdica De Bellvitge	Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012022496A2 (en)	2010-08-19	2012-02-23	Per Sonne Holm	Method for killing tumor stem cells
SG11201507393TA (en)	2013-03-14	2015-10-29	Salk Inst For Biological Studi	Oncolytic adenovirus compositions
PL3198009T3 (pl)	2014-09-24	2022-01-24	Salk Institute For Biological Studies	Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7015551B2 (ja)	2016-02-23	2022-02-15	ソークインスティテュートフォーバイオロジカルスタディーズ	ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja)	2016-02-23	2022-04-14	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en)	2016-12-12	2018-06-21	Salk Institute For Biological Studies	Tumor-targeting synthetic adenoviruses and uses thereof
JP7260173B2 (ja)	2017-04-21	2023-04-18	ベイラーカレッジオブメディスン	腫瘍溶解性ウイルス療法および免疫療法
JP7430395B2 (ja)	2018-04-09	2024-02-13	ソークインスティテュートフォーバイオロジカルスタディーズ	複製特質が増強された腫瘍溶解性アデノウイルス組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2051289C (en) *	1990-09-14	2002-11-26	Robert L. Martuza	Viral mediated destruction of neoplastic cells

1994
- 1994-02-16 DK DK98121753T patent/DK0931830T3/da active
- 1994-02-16 DE DE69426841T patent/DE69426841T2/de not_active Expired - Lifetime
- 1994-02-16 EP EP98121753A patent/EP0931830B1/en not_active Expired - Lifetime
- 1994-02-16 WO PCT/US1994/002049 patent/WO1994018992A1/en not_active Ceased
- 1994-02-16 DE DE69417734T patent/DE69417734T2/de not_active Expired - Lifetime
- 1994-02-16 ES ES98121753T patent/ES2157109T3/es not_active Expired - Lifetime
- 1994-02-16 AT AT94910177T patent/ATE178490T1/de active
- 1994-02-16 AT AT98121753T patent/ATE199568T1/de active
- 1994-02-16 PT PT98121753T patent/PT931830E/pt unknown
- 1994-02-16 AU AU62722/94A patent/AU682854B2/en not_active Expired
- 1994-02-16 DK DK94910177T patent/DK0689447T3/da active
- 1994-02-16 EP EP94910177A patent/EP0689447B1/en not_active Expired - Lifetime
- 1994-02-16 JP JP51929494A patent/JP3556666B2/ja not_active Expired - Lifetime
- 1994-02-16 ES ES94910177T patent/ES2134346T3/es not_active Expired - Lifetime
- 1994-02-16 CA CA002152941A patent/CA2152941C/en not_active Expired - Lifetime
1999
- 1999-06-01 GR GR990401479T patent/GR3030385T3/el unknown
2001
- 2001-05-22 GR GR20010400768T patent/GR3035914T3/el unknown
2003
- 2003-12-25 JP JP2003431544A patent/JP2004115543A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PT931830E (pt)	2001-08-30
AU682854B2 (en)	1997-10-23
ATE178490T1 (de)	1999-04-15
DK0689447T3 (da)	1999-10-18
DE69417734D1 (de)	1999-05-12
EP0689447A4 (en)	1997-06-04
GR3035914T3 (en)	2001-08-31
EP0689447B1 (en)	1999-04-07
WO1994018992A1 (en)	1994-09-01
JP2004115543A (ja)	2004-04-15
ATE199568T1 (de)	2001-03-15
DE69426841T2 (de)	2001-09-06
DE69417734T2 (de)	1999-10-07
JP3556666B2 (ja)	2004-08-18
DE69426841D1 (de)	2001-04-12
ES2134346T3 (es)	1999-10-01
CA2152941A1 (en)	1994-09-01
EP0931830A2 (en)	1999-07-28
EP0931830B1 (en)	2001-03-07
GR3030385T3 (en)	1999-09-30
EP0931830A3 (en)	2000-07-12
EP0689447A1 (en)	1996-01-03
AU6272294A (en)	1994-09-14
CA2152941C (en)	2003-04-22
JPH08507076A (ja)	1996-07-30
ES2157109T3 (es)	2001-08-01

Publication	Publication Date	Title
DK0689447T3 (da)	1999-10-18	Cytopatiske vira til behandling af og profylakse for neoplasia
DK0958371T3 (da)	2004-04-13	Cytopatiske vira til behandling og forebyggelse af neoplasi
DE69632256D1 (de)	2004-05-27	Antivirale proteine, dafür kodierende dna, und deren verwendung
WO1995032298A3 (en)	1996-06-06	Safe vectors for gene therapy
DK1252323T3 (da)	2006-04-03	Virus-stammer til den onkolytiske behandling af cancer
ES511668A0 (es)	1983-08-01	"metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
NO20020571L (no)	2002-04-05	Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
ATE116637T1 (de)	1995-01-15	Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
DE69133022D1 (de)	2002-07-04	Viral verursachte Zerstörung von Neoplastzellen
CA2130360A1 (en)	1993-08-21	Sulfonic Acid Derivatives in the Treatment of Viral Diseases
DK0652957T3 (da)	1997-10-27	Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
MXPA02007271A (es)	2004-07-30	Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
ES2113910T3 (es)	1998-05-16	Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
AU2833789A (en)	1989-07-13	Non-reverting rna viruses
DK90090A (da)	1990-04-10	Fremgangsmaade til fremstilling af naturligt hiv gp160
DK0480391T3 (da)	1996-04-22	Emulgatorfrie emulsionspolymerer, deres fremstilling og deres anvendelse i farmaceutiske præparater med forlænget frigivelse af virksomt stof
LV10384A (lv)	1995-02-20	Sastavs asins plazmas stabilizacijai pasterizacijas laika
AU630099B2 (en)	1992-10-22	Non-reverting rna viruses
DE69210737D1 (de)	1996-06-20	Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE69422980D1 (de)	2000-03-16	Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen
DE69006187D1 (de)	1994-03-03	Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.